Interactions Between BRD4S, LOXL2, and MED1 Drive Cell Cycle Transcription in Triple-Negative Breast Cancer

Investigators demonstrated that the simultaneous inhibition of lysyl oxidase-like 2 (LOXL2) and bromodomain-containing protein 4 (BRD4) synergistically limited TNBC proliferation in vitro and in vivo.